156 related articles for article (PubMed ID: 9123701)
1. Prostate cancer mortality in northern Sweden, with special reference to tumor grade and patient age.
Grönberg H; Damber L; Jonson H; Damber JE
Urology; 1997 Mar; 49(3):374-8. PubMed ID: 9123701
[TBL] [Abstract][Full Text] [Related]
2. Survival in prostate carcinoma--outcomes from a prospective, population-based cohort of 8887 men with up to 15 years of follow-up: results from three countries in the population-based National Prostate Cancer Registry of Sweden.
Aus G; Robinson D; Rosell J; Sandblom G; Varenhorst E;
Cancer; 2005 Mar; 103(5):943-51. PubMed ID: 15651057
[TBL] [Abstract][Full Text] [Related]
3. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
[TBL] [Abstract][Full Text] [Related]
4. Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE.
Ryan CJ; Elkin EP; Cowan J; Carroll PR
Cancer; 2007 Jul; 110(1):81-6. PubMed ID: 17516446
[TBL] [Abstract][Full Text] [Related]
5. The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival.
Varenhorst E; Garmo H; Holmberg L; Adolfsson J; Damber JE; Hellström M; Hugosson J; Lundgren R; Stattin P; Törnblom M; Johansson JE
Scand J Urol Nephrol; 2005; 39(2):117-23. PubMed ID: 16019764
[TBL] [Abstract][Full Text] [Related]
6. Hereditary prostate cancer: clinical characteristics and survival.
Bratt O; Damber JE; Emanuelsson M; Grönberg H
J Urol; 2002 Jun; 167(6):2423-6. PubMed ID: 11992050
[TBL] [Abstract][Full Text] [Related]
7. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.
Sweat SD; Bergstralh EJ; Slezak J; Blute ML; Zincke H
J Urol; 2002 Aug; 168(2):525-9. PubMed ID: 12131302
[TBL] [Abstract][Full Text] [Related]
8. Mortality of patients with clinically localized prostate cancer treated with observation for 10 years or longer: a population based registry study.
Brasso K; Friis S; Juel K; Jørgensen T; Iversen P
J Urol; 1999 Feb; 161(2):524-8. PubMed ID: 9915440
[TBL] [Abstract][Full Text] [Related]
9. Deferred treatment of clinically localized low-grade prostate cancer: actual 10-year and projected 15-year follow-up of the Karolinska series.
Adolfsson J; Steineck G; Hedlund PO
Urology; 1997 Nov; 50(5):722-6. PubMed ID: 9372882
[TBL] [Abstract][Full Text] [Related]
10. "Just Another Statistic".
Machtay M; Glatstein E
Oncologist; 1998; 3(3):III-IV. PubMed ID: 10388105
[TBL] [Abstract][Full Text] [Related]
11. [Natural disease course in untreated early prostatic carcinoma--the Orebro Study].
Johansson JE
Praxis (Bern 1994); 2001 Sep; 90(36):1507-14. PubMed ID: 11593906
[TBL] [Abstract][Full Text] [Related]
12. Reliability of death certificates in prostate cancer patients.
Fall K; Strömberg F; Rosell J; Andrèn O; Varenhorst E;
Scand J Urol Nephrol; 2008; 42(4):352-7. PubMed ID: 18609293
[TBL] [Abstract][Full Text] [Related]
13. Surveillance and deferred treatment for localized prostate cancer. Population based study in the National Prostate Cancer Register of Sweden.
Stattin P; Holmberg E; Bratt O; Adolfsson J; Johansson JE; Hugosson J;
J Urol; 2008 Dec; 180(6):2423-9; discussion 2429-30. PubMed ID: 18930283
[TBL] [Abstract][Full Text] [Related]
14. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy.
Beyer DC; McKeough T; Thomas T
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1299-305. PubMed ID: 15817331
[TBL] [Abstract][Full Text] [Related]
15. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort.
Albertsen PC; Hanley JA; Penson DF; Barrows G; Fine J
J Urol; 2007 Mar; 177(3):932-6. PubMed ID: 17296379
[TBL] [Abstract][Full Text] [Related]
16. Primary causes of death after permanent prostate brachytherapy.
Bittner N; Merrick GS; Galbreath RW; Butler WM; Wallner KE; Allen ZA; Brammer SG; Moyad M
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):433-40. PubMed ID: 18448268
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure.
D'Amico AV; Cote K; Loffredo M; Renshaw AA; Chen MH
J Urol; 2003 Apr; 169(4):1320-4. PubMed ID: 12629352
[TBL] [Abstract][Full Text] [Related]
18. The 20-Yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity.
Adolfsson J; Tribukait B; Levitt S
Eur Urol; 2007 Oct; 52(4):1028-35. PubMed ID: 17467883
[TBL] [Abstract][Full Text] [Related]
19. Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men.
Gong Z; Agalliu I; Lin DW; Stanford JL; Kristal AR
Cancer Causes Control; 2008 Feb; 19(1):25-31. PubMed ID: 17906959
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]